The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery
Year: 2025
Type: review
Abstract: Down syndrome (DS) is a genetic form of Alzheimer's disease (AD) that offers crucial insights into AD pathogenesis. The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal biomarker cohort studying AD's natural history and clinical trials in DS. DABNI included 1135 participants (mean age 42.82, 46.3% female). At baseline, 673 participants were cognitively stable, 113 had prodromal AD, 239 had AD dementia, and 110 were uncertain due to non-AD conditions. Over 10 years, > 10000 clinical visits were conducted; follow-up showed that progression to symptomatic AD before age 40 was rare, but rates increased after age 50 (> 50% within 5 years). Neuropsychological and biomarker assessments demonstrated excellent diagnostic performance and a predictable sequence of changes, similar to autosomal dominant AD. DABNI participates in AD clinical trials and produced approximately 100 publications. The 10-year DABNI study provided critical insights into DS-associated AD (DSAD) and serves as a key platform for DS clinical trials. HIGHLIGHTS: Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) is a population-based multimodal cohort studying Alzheimer's disease in Down syndrome. Over 10 years, 1135 participants contributed to more than 10000 clinical visits and extensive biomarker studies. DABNI findings have transformed the understanding of Alzheimer's disease in Down syndrome, reinforcing its classification as a genetic form of the disease. The cohort integrates clinical care and research, enhancing early detection and patient management. DABNI supports clinical trials and has produced over 100 publications advancing Down syndrome-related Alzheimer's research.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.70259
Authors: Laura Videla, Bessy Benejam, Isabel Barroeta, Susana Fernandez, Miren Altuna, Javier Arranz, Íñigo Rodríguez‐Baz, José Enrique Arriola‐Infante, Lucía Maure‐Blesa, Laura del Hoyo Soriano, Ignacio Illán‐Gala, Teresa Estellés, Aida Sanjuan, Lídia Vaqué‐Alcázar, Mateus Rozalem Aranha, Alejandra O. Morcillo‐Nieto, Sarah Erzsebet Zsadanyi, Maria Franquesa‐Mullerat, Sílvia Valldeneu, María Belén Sánchez‐Saudinós, Concepción Padilla, Mireia Carreras, Oriol Lorente, Natalia Valle‐Tamayo, Érika Sánchez‐Aced, Oriol Dols‐Icardo, Sònia Sirisi, Laia Muñoz, Soraya Torres, Shaima El Bounasr El Bennadi, Oriol Sánchez, Diana Garzón, Laia Ribas, Sumia Elbachiri, Cecilia Mota, Mireia Tondo, Valle Camacho, Sandra Giménez, Constance Delaby, Olivia Belbin, María Florencia Iulita, Víctor Montal, Jordi Pegueroles, Eduard Vilaplana, Jordi Clarimón, Sofía González‐Ortiz, Laura Molina‐Porcel, Iban Aldecoa, Daniel Alcolea, Alexandre Bejanin, Sebastià Videla, Rafael Blesa, Alberto Lleó, María Carmona‐Iragui, Juan Fortea
Institutions: Universitat Autònoma de Barcelona, Hospital de Sant Pau, Biomedical Research Networking Center on Neurodegenerative Diseases, Fundacion CITA Alzheimer, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Universitat Oberta de Catalunya, Université de Montpellier, Barcelona Supercomputing Center, Lundbeck (Denmark), Hospital Clínic de Barcelona, Hospital Del Mar, Parc de Salut, Hospital Universitari Germans Trias i Pujol
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
Funders: Alzheimer's Association, Fondation Jérôme Lejeune, “la Caixa” Foundation, Global Brain Health Institute, European Commission, Fondation Jérôme Lejeune, Fundación Tatiana Pérez de Guzmán el Bueno, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, National Institutes of Health, Horizon 2020 Framework Programme, Instituto de Salud Carlos III, European Regional Development Fund, National Institute on Aging, H2020 European Institute of Innovation and Technology
Awards: Interacción de la inflamación del sistema nervioso periférico y central en la enfermedad de Alzheimer y el síndrome de Down, G1178615512, G131695710, Caracterización multimodal de las etapas prodrómicas del espectro Alzheimer-Lewy, G1367821143, Multimodal Imaging of Small Vessel Disease in Genetic AD, Avanzando la clasificación de la demencia frontotemporal y la esclerosis lateral amiotrófica mediante neuroimagen microestructural y funcional, y biomarcadores sanguíneos de neurodegeneración y neuroinflamación, DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's Disease, G1662666259, G1838929904, Acúmulo de Proteína Precursora de Amiloide-C99 (APP-C99) como mecanismo de enfermedad en la enfermedad de Alzheimer: implicaciones terapéuticas., G210922279, G2120928055, The Role of Inflammation and NGF Dysfunction in the Evolution of AlzheimerDisease Pathology in Down syndrome, G2362306273, G2417794953, Sleep and Temperature Disturbance as risk factors for Alzheimer's Disease in Down Syndrome: a Longitudinal Study, G2628364946, G295477303, Cambios Microestructurales en la Degeneración Lobular Frontotemporal: Implicaciones diagnósticas, Pronósticas y Etiológicas, G3012247180, Ensayo en fase III para evaluar la seguridad y eficacia de LEvetiracetam para prevenir las crisiS epilépticas en adultos con síndrome de Down y enfermedad de Alzheimer, G3329934726, G3559709381, G3590198064, Síndrome de apnea-hipopnea del sueño y síndrome de Down. Estudio multimodal del sueño y cognición, biomarcadores plasmáticos y de líquido cefalorraquídeo de enfermedad de Alzheimer y resonancia magnética craneal, Caracterización de la inflamación relacionada con amiloide: nuevos marcadores inflamatorios y su impacto en la macroestructural y microestructura cortical en la enfermedad de Alzheimer preclínica y prodrómica, G367498634, G4128068045, G434337789, G4453436814, Clinical trials to prevent Alzheimer's Disease in Down Syndrome, G4605335268, G4701729962, G4937468798, Utilidad diagnóstica de Aß42 y Aß42/40 en LCR y plasma para detectar amiloidosis cerebral y correlación con marcadores subrogados de producción de ß-amiloide en enf. de Alzheimer, G5681354352, Evaluation of Cortical Microinfarcts in Individuals with Down Syndrome, G6049260834, Neuroimagen multimodal de la enfermedad de pequeños vasos relacionada con la enfermedad de Alzheimer en el síndrome de Down, G676330562, Assessing Peripheral Inflammation in DS at Different Stages of AD, G7093738275, G7313350453, Tau pathology in Down syndrome and Alzheimer's, Unveiling the impact of biological sex along sporadic and genetic FTLD, G8047729998, Estudio de biomarcadores bioquímicos y de imagen de angiopatía amiloide cerebral en el continuum de la enfermedad de Alzheimer esporádica y asociada al síndrome de Down, Marcadores sinápticos en la enfermedad de Alzheimer, Multimodal Assessment of Brain Inflammatory Biomarkers in DS-associated AD, G8289202400, G8418255654, Biological Correlates of Alzheimer in Down Syndrome., APP-C99 como componente patogénico clave y una diana terapéutica en la enfermedad de Alzheimer, G8824911526, G8858395165, G968800864
OpenAlex ID: W4411397895